Short Interest in Apollomics, Inc. (NASDAQ:APLM) Rises By 34.9%

Apollomics, Inc. (NASDAQ:APLM) was the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 209,300 shares, a growth of 34.9% from the March 31st total of 155,100 shares. Approximately 0.3% of the shares of the company are short sold. Based on an average daily trading volume, of 191,500 shares, the short-interest ratio is presently 1.1 days.

Analyst Ratings Changes

Separately, HC Wainwright cut their target price on shares of Apollomics from $17.00 to $5.00 and set a “buy” rating for the company in a research report on Monday, April 1st.

Apollomics Trading Down 4.5 %

Shares of Apollomics stock traded down $0.02 on Friday, reaching $0.45. The stock had a trading volume of 245,270 shares, compared to its average volume of 183,745. Apollomics has a 1 year low of $0.40 and a 1 year high of $6.45. The business’s 50 day moving average is $0.62 and its two-hundred day moving average is $0.84.

Institutional Investors Weigh In On Apollomics

A hedge fund recently bought a new stake in Apollomics stock. Powell Investment Advisors LLC bought a new stake in shares of Apollomics, Inc. (NASDAQ:APLM) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 130,297 shares of the company’s stock, valued at approximately $98,000. Powell Investment Advisors LLC owned approximately 0.15% of Apollomics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 19.13% of the company’s stock.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.